Initiator Pharma reports positive Phase IIa clinical data for IPED2015 in patients with severe Erectile Dysfunction
Initiator Pharma A/S, a clinical-stage biotech company that is developing a novel treatment of erectile dysfunction (ED), today announced statistically significant results on key efficacy endpoints in severe ED patients after a single administration of IPED2015. Moreover, no observations of critical adverse events were recorded.The Phase IIa study which included patients suffering from servere Erectile Dysfunction (ED) has been completed satisfactorily. The study has demonstrated promising statistical significant efficacy data on ED. Besides, there has been no reporting of critical safety